Showing results (1151-1160 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 1, 1990
Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504)R L Stephens, P Goodman, E D Crawford, et al.
Investigational New Drugs|March 15, 2011
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortiumHelen J Mackay, Heather J Au, Elaine McWhirter, et al.
Investigational New Drugs|May 20, 2020
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trialKazuhisa Nakashima, Yuichi Ozawa, Haruko Daga, et al.
Investigational New Drugs|May 9, 2020
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trialBastien Cabarrou, Carlos Gomez-Roca, Marie Viala, et al.
Investigational New Drugs|August 21, 2021
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinomaHani Babiker, Peter J Schlegel, Lee G Hicks, et al.
Investigational New Drugs|May 4, 2021
Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinomaChen Xiong, Zhihuai Wang, Guifu Wang, et al.
Investigational New Drugs|August 3, 2021
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancerAmmu V V V Ravi Kiran, Garikapati Kusuma Kumari, Praveen T Krishnamurthy
Investigational New Drugs|July 12, 2015
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancerToshihiko Doi, Takayuki Yoshino, Nozomu Fuse, et al.
Investigational New Drugs|May 19, 2015
Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipidsEmil Bujak, Francesca Pretto, Dario Neri
Investigational New Drugs|May 19, 2015
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195B J Eigl, S North, E Winquist, et al.
Pageof 372